[Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma].
Paclitaxel-carboplatin combination chemotherapy has been administered worldwide in the first-line adjuvant treatment of epithelial ovarian cancers since the mid 1990's. Goal was to evaluate the early results of the first-line paclitaxel-carboplatin treatment practiced at the Gynecological Department of National Institute of Oncology, Budapest between November 2000 and August 2002. Paclitaxel and carboplatin were administered in the doses of 175 mg/m2/3 h and AUC 5, respectively. Average age of patients was 54 +/- 9.8 years. The patients were considered into stage I in 18.4% and in stage II-III and IV in 4.6%, 52.9% and 8%. The surgeon did not reported the stage in 16.1% of patients. Statistical analysis was performed by the product limit method of Kaplan and Meier. The progression free interval was found to be 100%, 50%, 71.7% and 71.4% in stages I, II, III and IV, at the end of the 6th chemotherapy course and decreased to 100%, 50%, 52.2% and 42.9% in the same stages at the time of evaluation (16 December 2002). Authors found a 77% CR in the patients at the end of chemotherapy. Only progression free interval till the end of treatment could be evaluated because of the short follow up period. The observed 77% CR is similar to the data of the literature. The final conclusions will be made by later follow up.